Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

(2020) Miriam Marqués et al.   CANCER RESEARCH

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

(2020) Fabio Nicolini et al.   Frontiers in Oncology

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells

(2019) Daniele Cretella et al.   Scientific Reports

Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation

(2019) Mara Bonelli et al.   BIOCHEMICAL PHARMACOLOGY

Metabolic rewiring and redox alterations in malignant pleural mesothelioma

(2019) Loredana Urso et al.   BRITISH JOURNAL OF CANCER

mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer

(2019) Karen Griselda de la Cruz López et al.   Frontiers in Oncology

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

(2018) Daniele Cretella et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues

(2018) Eric S. Goetzman et al.   Frontiers in Endocrinology

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

(2018) Julija Hmeljak et al.   Cancer Discovery

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

(2017) Silvia La Monica et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis

(2017) Jonathan Cooper et al.   MOLECULAR CANCER THERAPEUTICS

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells

(2017) Mara A. Bonelli et al.   NEOPLASIA

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing

(2016) Marieke Hylebos et al.   Journal of Thoracic Oncology

Genomic Landscape of Malignant Mesotheliomas

(2016) S. Kato et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt

(2016) Jinfang Zhang et al.   MOLECULAR CELL

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

(2016) Raphael Bueno et al.   NATURE GENETICS

mTOR coordinates protein synthesis, mitochondrial activity and proliferation

(2015) Masahiro Morita et al.   CELL CYCLE

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

(2015) Marco Lo Iacono et al.   Journal of Thoracic Oncology

MYC, Metabolism, and Cancer

(2015) Z. E. Stine et al.   Cancer Discovery

MYC and Mitochondrial Biogenesis

(2014) F. Morrish et al.   Cold Spring Harbor Perspectives in Medicine

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling

(2013) Claudia Fumarola et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular pathogenesis of malignant mesothelioma

(2013) Y. Sekido   CARCINOGENESIS

mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation

(2013) Masahiro Morita et al.   Cell Metabolism

Re-thinking cell cycle regulators: the cross-talk with metabolism

(2013) Lluis Fajas   Frontiers in Oncology

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

(2012) Andrea Cavazzoni et al.   CANCER LETTERS

c-Myc and Cancer Metabolism

(2012) D. M. Miller et al.   CLINICAL CANCER RESEARCH

Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma

(2012) Kyoichi Kaira et al.   EUROPEAN JOURNAL OF CANCER

Akt and c-Myc Differentially Activate Cellular Metabolic Programs and Prime Cells to Bioenergetic Inhibition

(2009) Yongjun Fan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

(2008) A. Cavazzoni et al.   MOLECULAR CANCER THERAPEUTICS